Mission Statement, Vision, & Core Values (2026) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Founded in 1998, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) has grown into a dual-listed multinational operating in over 50 countries and regions with a diversified portfolio spanning heparin products, CDMO services for large-molecule biologics, and innovative drug R&D; its vertically integrated heparin industrial chain positions the company as an industry leader while a sustained focus on high-quality, safe, and effective medicines and patient-centric development drives strategic investments and global expansion rooted in scientific rigor, operational efficiency, inclusive culture, and a vision to become a world-leading innovative pharmaceutical company.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Intro

• Founded: 1998
• Listings: Dual-listed (Hong Kong and mainland China); HKEX ticker 9989.HK
• Global footprint: Operations and customers in >50 countries/regions
• Core business lines: Heparin products, CDMO for biologics (large molecules), innovative drug R&D and commercialization

• Heparin leadership: Vertically integrated supply chain to mitigate supply disruption risk and ensure consistent quality for anticoagulant APIs and finished formulations.
• CDMO capacity: Development and manufacturing services targeted at complex biologics (large molecules), supporting global biopharma customers with process development, GMP production, and technical transfer.
• R&D and innovation: Active pipeline and licensing strategies to acquire, develop, and commercialize differentiated drug candidates aimed at unmet medical needs.

• Revenue drivers: Core heparin product sales and expanding CDMO services; innovative drug commercialization expected to contribute growth over medium term.
• Risk management: Vertical integration and diversified customer base reduce concentration risk associated with single-source supply of critical APIs.
• Growth levers: Geographic expansion, CDMO capacity scaling, in-licensing/acquisition of differentiated assets, and advancing internal pipeline assets through clinical development.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Overview

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) operates with a clearly articulated mission to discover, develop, and commercialize high-quality, safe, and effective medicines and services to address patients' unmet needs. This mission underpins strategic choices across R&D investment, manufacturing quality systems, global partnerships, and patient-access programs.

• Patient-centric focus: prioritizing therapeutic gaps where clinical need is highest (e.g., heparin and anticoagulant therapies, nephrology, and oncology adjuncts).
• Quality and safety emphasis: GMP manufacturing sites, regulatory compliance across CN, EU, and other markets to ensure product integrity.
• Innovation commitment: sustained R&D investment to advance biologics, generic complex drugs, and specialty APIs.
• Accessibility: programs and pricing strategies aimed at widening patient access in China and select overseas markets.

The mission's continuity over time has manifested in measurable actions and resource allocation. Key company metrics that reflect this strategic orientation include revenue composition, R&D intensity, operational scale, and capital-market valuation.

• Strategic alignment: R&D budget prioritizes high-unmet-need areas to translate the mission into pipeline outputs and commercial products.
• Quality metrics: routine regulatory inspections and batch-release data drive continuous improvement to meet the "high-quality, safe, and effective" standard.
• Global access: export revenues and licensing deals indicate progress toward broader patient reach beyond domestic markets.

Operational and financial priorities derived from the mission include enhancing clinical development capabilities, expanding manufacturing capacity to ensure supply security, and maintaining disciplined capital allocation to balance growth and profitability. For additional investor-focused context and shareholder activity, see: Exploring Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Mission Statement

• Ambition to lead in pharmaceutical innovation on a global scale rather than remain regionally focused.
• Commitment to develop novel therapies and technological platforms addressing evolving healthcare challenges, especially in hematology, nephrology, and related therapeutic areas.
• A long-term strategic orientation guiding capital allocation toward R&D, regulatory approvals, manufacturing scale-up, and international market entry.
• An organizational priority on talent, partnership, and scientific excellence to sustain leadership.

• R&D intensity: The vision drives elevated R&D investment and capacity-building (preclinical pipelines, clinical trials, biomanufacturing capabilities), with a focus on first-in-class and best-in-class biologics and peptide therapeutics.
• Global expansion: Market-entry strategies prioritize regulatory approvals in major jurisdictions and partnerships with global pharma and CROs to accelerate commercialization.
• Manufacturing scale & quality: Investment in GMP facilities and quality systems to support global supply chains and export-ready product lines.
• Talent & partnerships: Building international scientific teams and licensing/collaboration deals to import complementary capabilities and accelerate time-to-market.

• R&D expenditure priority: Capital allocation emphasizes sustained funding for discovery, IND-enabling studies, and multi-regional clinical trials to support global registration strategies.
• CapEx for manufacturing: Investments target capacity expansion and biologics-grade facilities aligned with international GMP standards to meet export demand.
• Commercial investment: Resources directed to build overseas regulatory, medical affairs, and commercial teams to convert approvals into market share.

• Pipeline expansion and clinical-stage programs demonstrate a shift from local generics and heparin-related products toward innovative biologics and specialty therapies.
• Strategic alliances and cross-border collaborations support faster regulatory access and wider distribution networks.
• Upgrading manufacturing and QA/QC systems to international standards supports the ambition to serve global markets reliably.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Vision Statement

• Scientific rigor and integrity: Prioritize evidence-based R&D, GMP-compliant manufacturing, and end-to-end quality assurance to ensure patient safety and regulatory compliance.
• Efficiency and excellence: Drive scalable operations, lean manufacturing, and performance-based incentives to maximize productivity and shareholder value.
• Innovation and initiative: Invest in next-generation molecules, process innovations, and new business models to capture growth opportunities across markets.
• Diversity and inclusivity: Cultivate a workplace that respects cultural differences, encourages candid collaboration, and attracts global talent.

• Respect for science and integrity: Compliance with international regulatory standards (e.g., GMP, ISO) and reinforced pharmacovigilance systems to ensure product safety.
• Result orientation and continuous improvement: KPIs for yield, cycle times, and OEE (overall equipment effectiveness) to raise productivity and lower unit costs.
• Proactive innovation: Pipeline diversification targets, including first-in-class or best-in-class candidates and collaborations with academic and industrial partners.
• Inclusive culture and teamwork: Global hiring, cross-border project teams, and diversity metrics to strengthen creativity and global market responsiveness.